<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report the performance evaluation of a non-quantitative reverse-hybridization assay (KRAS-BRAF StripAssay) designed for the simultaneous detection of 10 mutations in codons 12 and 13 of the KRAS gene and BRAF mutation V600E </plain></SENT>
<SENT sid="1" pm="."><plain>Dilution experiments using DNA from <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines or from formalin-fixed paraffin-embedded (FFPE) <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) tissue were performed to assess assay sensitivity </plain></SENT>
<SENT sid="2" pm="."><plain>Using 50 ng of total DNA (mutant and <z:mp ids='MP_0002169'>wild-type</z:mp>), the KRAS-BRAF StripAssay demonstrated a detection limit of 1% mutant sequence in a background of <z:mp ids='MP_0002169'>wild-type</z:mp> DNA </plain></SENT>
<SENT sid="3" pm="."><plain>With respect to BRAF V600E, the KRAS-BRAF StripAssay was evaluated using 60 FFPE <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> samples previously analyzed by high resolution melting (HRM) </plain></SENT>
<SENT sid="4" pm="."><plain>Test strip hybridization identified 2/60 (3%) samples to carry the BRAF V600E mutation, and results were in agreement with those obtained by HRM analysis </plain></SENT>
<SENT sid="5" pm="."><plain>This work demonstrates the KRAS-BRAF StripAssay to be a robust and sensitive method for the detection of common KRAS/BRAF mutations in genomic DNA isolated from FFPE tissue samples </plain></SENT>
</text></document>